Welcome to our dedicated page for Genpact SEC filings (Ticker: G), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Genpact Limited (NYSE: G) SEC filings, including current reports, registration statements, and other disclosures filed with the U.S. Securities and Exchange Commission. Genpact describes itself as an agentic and advanced technology solutions company, and its filings offer detailed insight into how it applies process intelligence and artificial intelligence within its business, as well as how it structures its capital and governance.
Investors can review Form 8-K filings for information on material events such as quarterly financial results, leadership changes, board appointments, and financing transactions. For example, recent 8-Ks discuss third quarter 2025 financial results, appointments of directors and senior officers, and the completion of a public offering of 4.950% Senior Notes due 2030 by Genpact UK Finco plc and Genpact USA, Inc., guaranteed by Genpact and Genpact Luxembourg.
Genpact also uses shelf registration statements and prospectus supplements on Form S-3 to register securities offerings, as reflected in the documentation supporting its 2030 senior notes. Credit agreement guarantees and supplemental indentures are described in exhibits to these filings, outlining covenants, guarantees, and change-of-control provisions relevant to Genpact’s debt structure.
On Stock Titan, AI-powered tools can help summarize lengthy filings, highlight key terms in 10-K and 10-Q reports, and surface notable items from Form 4 insider transaction reports where applicable. Real-time updates from EDGAR ensure that new Genpact filings appear promptly, allowing users to monitor financial performance, capital markets activity, and corporate governance developments through the company’s official regulatory disclosures.
Genpact Limited (G) officer or insider filed a Form 144 to sell 55,000 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $2,384,883.50 and an approximate sale date of 09/11/2025. The filing reports 174,270,076 shares outstanding for the issuer, implying the notice covers a small fraction of outstanding stock.
The securities to be sold were acquired partly by a stock option exercise on 09/11/2025 (40,000 shares, paid in cash) and partly as performance shares granted 01/10/2022 (15,000 shares). The filer states there were no shares sold in the past three months and attests they have no undisclosed material adverse information.
Donald J. Klunk, identified as Chief Accounting Officer, reported two non-derivative transactions in Genpact Limited (G). On 09/02/2025 1,468 shares were withheld for taxes upon vesting of restricted share units at a price of $45.34, leaving 10,135 shares beneficially owned after that transaction. On 09/03/2025 he sold 2,695 shares at $44.77, leaving 7,440 shares beneficially owned following the sale. The filing notes 252 shares were acquired under the Genpact Employee Stock Purchase Plan since his prior Form 4 on March 13, 2025, and he currently holds 673 ESPP shares. The form is signed by an attorney-in-fact on 09/04/2025.
Genpact Limited (G) notice: an individual who received 2,695 restricted common shares from the issuer on 08/31/2025 intends to sell those shares on or about 09/03/2025. The filer lists Morgan Stanley Smith Barney LLC as the broker and values the shares' aggregate market value at $120,641.68 based on outstanding common shares of 174,270,076. The filing reports no other sales in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Genpact Limited (G) insider transaction: Sameer Dewan, Senior Vice President, reported selling 20,078 common shares on 08/28/2025 at $45 per share, leaving him with 89,148 shares beneficially owned after the sale. The Form 4 was signed by an attorney-in-fact on 08/29/2025. The filing shows a direct disposition of shares and does not disclose any derivative transactions or a 10b5-1 plan.
Genpact Limited (G) submitted a Form 144 notifying a proposed sale of 20,078 common shares via Morgan Stanley Smith Barney on the NYSE, with an aggregate market value of $903,510 and an approximate sale date of 08/28/2025. The filing shows the shares were acquired on 01/10/2025 from the issuer as 12,236 restricted stock and 7,842 performance shares, with payment dates listed as 01/10/2025 and no cash financing arrangements disclosed. The total outstanding common shares noted are 174,270,076, so the proposed sale represents a de minimis portion of the outstanding float. The filer certifies no undisclosed material adverse information and no sales in the past three months are reported.
Anil Nanduru, Senior Vice President at Genpact Limited (G), reported two open-market sales of company common shares on Aug 21–22, 2025. He sold 18,218 shares on 08/21/2025 at $44.50 per share and 9,744 shares on 08/22/2025 at $45.50 per share, reducing his beneficial ownership to 89,846 common shares after the transactions. The filing notes that his total holdings include 237 shares received via dividend reinvestment since his prior Form 4. The Form 4 is signed by an attorney-in-fact for the reporting person.
Genpact Limited insider Form 4: Senior Vice President Riju Vashisht reported two open-market sales of Genpact (G) common shares on 08/22/2025. The first sale disposed of 17,608 shares at a weighted average price of $45.61, leaving 130,201 shares beneficially owned. The second sale disposed of 7,931 shares at a weighted average price of $45.57, leaving 122,270 shares beneficially owned. The combined number of shares sold was 25,539. The form notes the price ranges for the sales and discloses the reporting person holds 4,154 shares via the Employee Stock Purchase Plan, including 160 shares acquired since the prior Form 4. The filing was signed by an attorney-in-fact on 08/25/2025.
Form 144 notice indicates a proposed sale of 9,744 common shares through Morgan Stanley Smith Barney on 08/22/2025 with an aggregate market value of $443,352.00. The shares were acquired as restricted stock from the issuer on 01/10/2025 and paid for on that date. The filer disclosed two prior sales on 08/21/2025 totaling 18,218 shares for gross proceeds of $810,701.00 (listed as $505,119.50 and $305,581.50). The notice includes the standard representation that the seller does not possess undisclosed material adverse information about the issuer.
Form 144 notice for Genpact Limited (symbol: G) discloses a proposed sale of 25,539 common shares through Morgan Stanley Smith Barney LLC on the NYSE with an aggregate market value of $1,164,468.47 and approximately 174,270,076 shares outstanding. The shares were acquired as performance shares: 17,608 on 01/10/2022 and 7,931 on 01/10/2023. No securities were reported sold by the selling person in the past three months. The filer certifies they are unaware of any undisclosed material adverse information and follows the Rule 144 disclosure process.
Genpact Limited (G) filing a Form 144 notifies the proposed sale of 18,218 common shares through Morgan Stanley Smith Barney LLC on the NYSE with an aggregate market value of $810,701.00. The shares were granted as performance shares and were acquired in two tranches: 11,351 on 01/10/2022 and 6,867 on 01/10/2023. The filing lists 174,270,076 shares outstanding for the class and indicates no reported sales by the seller in the past three months. The notice includes the seller’s representation that they are not aware of undisclosed material adverse information.